Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Island Pharmaceuticals Ltd ( (AU:ILA) ) just unveiled an update.
Island Pharmaceuticals has reported that the US Food & Drug Administration has requested additional time to finalise its response on the regulatory development pathway for Galidesivir under the Animal Rule, but has not issued any adverse feedback, sought extra data or changed its previously positive stance, including eligibility for Priority Review Voucher status. While awaiting more detailed guidance that will shape planned non-human primate studies in Marburg virus and broader clinical trial plans, the company is continuing study preparations, engagement with US government stakeholders and negotiations with potential study partners, positioning itself to move quickly into the next phase of Galidesivir’s development once the FDA’s program approval and clarifications are received.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.42 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian antiviral drug development company listed on the ASX that focuses on treatments for urgent viral diseases, public health emergencies and biosecurity threats. The company is pursuing a dual development strategy for its assets ISLA-101, a repurposed drug targeting dengue fever and other mosquito-borne diseases, and Galidesivir, a clinical-stage broad-spectrum antiviral active against more than 20 RNA viruses including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever.
Average Trading Volume: 536,745
Technical Sentiment Signal: Buy
Current Market Cap: A$117M
See more data about ILA stock on TipRanks’ Stock Analysis page.